Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial

IMPORTANCE: Patients with radioactive iodine–refractory differentiated thyroid cancer (RAIR-DTC) have a poor prognosis and limited treatment options. OBJECTIVE: To assess the efficacy and safety of apatinib, a highly selective vascular endothelial growth factor (VEGFR-2) inhibitor, in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yansong, Qin, Shukui, Li, Zhiyong, Yang, Hui, Fu, Wei, Li, Shaohua, Chen, Wenxin, Gao, Zairong, Miao, Weibing, Xu, Huiqin, Zhang, Qing, Zhao, Xinming, Bao, Jiandong, Li, Linfa, Ren, Yuan, Lin, Chenghe, Jing, Shanghua, Ma, Qingjie, Liang, Jun, Chen, Guang, Zhang, Hong, Zhang, Yifan, Zhou, Xianfeng, Sang, Yaxiong, Hou, Zhiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678901/
https://www.ncbi.nlm.nih.gov/pubmed/34913959
http://dx.doi.org/10.1001/jamaoncol.2021.6268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678901/
https://www.ncbi.nlm.nih.gov/pubmed/34913959
http://dx.doi.org/10.1001/jamaoncol.2021.6268

Ejemplares similares